Kangfuxin Enteric-coated Capsule

Using clinical remission rate, clinical effective rate, endoscopic response rate, mucosal healing rate, histological clinical remission rate and other efficacy indicators, a multicenter, randomized, double-blind, placebo-controlled clinical trial design was adopted to preliminarily evaluate the efficacy and safety of Kangfuxin Enteric-coated Capsules combined with mesalazine in the treatment of mild to moderate active ulcerative colitis.